Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 305

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer

Open access
Bott, Matthew J., Yang, Stephen C., Park, Bernard J., Adusumilli, Prasad S., Rusch, Valerie W., Isbell, James M., Downey, Robert J., Brahmer, Julie R., Battafarano, Richard, Bush, Errol, Chaft, Jamie, Forde, Patrick M., Jones, David R., Broderick, Stephen R. · 2019 · The Journal of Thoracic and Cardiovascular Surgery

Abstract

Objective We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the PD-1 checkpoint receptor, in patients with resectable non-small cell lung cancer (NSCLC). We analyzed perioperative outcomes to assess the safety of this strategy. Methods Patients with untreated stage I-IIIA NSCLC underwent neoadjuvant therapy with two cycles of nivolumab (3 mg/kg), 4 and 2 weeks before resection. Patients underwent invasive mediastinal staging as indicated and posttreatment computed tomography. Primary study endpoints were safety and feasibility of neoadjuvant nivolumab followed by pulmonary resection. Additional surgical details were collected through chart review. Results Of 22 patients enrolled, 20 underwent resection. One was unresectable; another had small cell histologic subtype. There were no delays to surgical resection. Median (range) time from first treatment to surgery was 33 (17–43) days. There were 15 lobectomies, 2 pneumonectomies, 1 bilobectomy, 1 sleeve lobectomy, and 1 wedge resection. Of 13 procedures attempted via a video-assisted thoracoscopic surgery (VATS) or robotic approach, 7 (54%) required thoracotomy. Median (range) operative time was 228 (132–312) minutes; estimated blood loss was 100 (25–1000) mL; length of hospital stay was 4 (2–17) days. There was no operative mortality. Morbidity occurred in 10 of 20 patients (50%). The most common postoperative complication was atrial arrhythmia (6/20 [30%]). Major pathologic response was identified in 9 of 20 patients (45%). Conclusion Neoadjuvant therapy with nivolumab was not associated with unexpected perioperative morbidity or mortality. More than half of VATS/robotic cases were converted to thoracotomy, often due to hilar inflammation and fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtcvs.2018.11.124

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

Metadata

Authors
Bott, M. J., Yang, S. C., Park, B. J., Adusumilli, P. S., Rusch, V. W., Isbell, J. M., Downey, R. J., Brahmer, J. R., Battafarano, R., Bush, E., Chaft, J., Forde, P. M., Jones, D. R., & Broderick, S. R.
Venue
The Journal of Thoracic and Cardiovascular Surgery
Publisher
Elsevier BV
Published
2019-07
Volume
158
Issue
1
Pages
269-276
ISSN
0022-5223 (ISSN-L)
OpenAlex
W2905289065
Cited by
305
References
25
FWCI
19.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.